Sort
30,917 grants matching “tumor microenvironment”
Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapy
$306,607Balveen Kaur · Brigham And Women'S Hospital · P01 · FY2023 · CA
IN VIVO MODULATION OF PROGRESSION IN COLON CANCER
$306,602Case Western Reserve University · R01 · FY2000 · CA
Next-Generation Engineered NK Cell Immunotherapy for Ovarian Cancer
$306,595Katy Rezvani · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Targeting EGFL6 in Ovarian Cancer
$306,593Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Bone-Targeted Therapies to Improve Bone Health and Prevent Relapse in Multiple Myeloma
$306,555Jesus Delgado-Calle · Univ Of Arkansas For Med Scis · R37 · FY2024 · CA
Targeting MFG-E8 as Melanoma Immunotherapy
$306,522Glenn Dranoff · Dana-Farber Cancer Inst · R01 · FY2014 · CA
Cyr61-induced breast cancer: Clinical relevance and therapeutic development
$306,490Ruth Lupu · Mayo Clinic Rochester · R01 · FY2010 · CA
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS
$306,482Ryan A Wilcox · University Of Michigan At Ann Arbor · R37 · FY2024 · CA
hiPS cells derived skeletal muscle progenitors and their extracellular vesicles for treatment of sarcopenia
$306,475Wanling Xuan · University Of South Florida · R01 · FY2022 · AG
Internalizing human antibody-targeted nanosized siRNA therapeutics
$306,391Bin Liu · University Of California, San Francisco · R01 · FY2013 · CA
Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy
$306,368Evette S Radisky · Mayo Clinic Jacksonville · R01 · FY2024 · CA
Preclinical development of VAX024 - a novel targeted combination STING agonist/oncolytic agent
$306,265Matthew Giacalone · Vaxiion Therapeutics, Inc. · R43 · FY2025 · CA
To Understand/Augment OX40-mediated Tumor Immunotherapy
$306,263Andrew D Weinberg · Providence Portland Medical Center · R01 · FY2011 · CA
To Understand/Augment OX40-mediated Tumor Immunotherapy
$306,263Andrew D Weinberg · Providence Portland Medical Center · R01 · FY2012 · CA
THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS
$306,248Ryan A Wilcox · University Of Michigan At Ann Arbor · R37 · FY2019 · CA
Artemin overexpression in oral cancer pain and carcinogenesis
$306,247Donna G Albertson · New York University · R01 · FY2024 · CA
Microenvironmental Influences in Cancer
$306,232Jin Chen · Vanderbilt University · T32 · FY2016 · CA
Bone Marrow MSCs/Pericytes: Gatekeepers Controlling Skeletal Metastasis.
$306,229Arnold I. Caplan · Case Western Reserve University · R01 · FY2013 · CA
Mechanistic Dynamic Study of Intranodal Chemokine-aided Antitumor Immune Priming
$306,229Alex Yee-Chen Huang · Case Western Reserve University · R01 · FY2013 · CA
Integrating Anti-invasive and Anti-growth Therapies Targeting Cancer Metastasis
$306,229Jian Cao · State University New York Stony Brook · R01 · FY2013 · CA
Characterization of Age-Related Changes in Stem Cell Behavior
$306,229Dana Leanne Jones · University Of California Los Angeles · R01 · FY2015 · AG
EphA2 kinase in prostate cancer
$306,229Bingcheng Wang · Case Western Reserve University · R01 · FY2013 · CA
Core 2: Analytical Core
$306,131Nathalie Yr Agar · Massachusetts Institute Of Technology · U54 · FY2024 · CA
Novel developmental regulation of non-canonical Wnt signaling
$306,083Jan L Christian · University Of Utah · R01 · FY2016 · HD
Intravital Microscopy Core
$306,070Roberto Weigert · Division Of Basic Sciences - Nci · ZIC · FY2024 · CA